Medpace Holdings (MEDP) EBIT (2015 - 2026)

Medpace Holdings (MEDP) has reported EBIT for 12 consecutive years, with $141.5 million the latest figure, recorded in Q1 2026.

• EBIT for Q1 2026 came in at $141.5 million, up 24.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $562.9 million (up 23.36% YoY), and the FY2025 annual result was $534.9 million, up 19.71% from the prior year.
• EBIT was $141.5 million for Q1 2026 at Medpace Holdings, down from $153.3 million in the prior quarter.
• Over five years, EBIT peaked at $153.3 million in Q4 2025 and troughed at $60.2 million in Q2 2022.
• Average EBIT over 5 years is $102.3 million, with a median of $104.1 million recorded in 2024.
• Year-over-year, EBIT soared 44.89% in 2022 and grew 9.08% in 2025.
• Over 5 years, EBIT stood at $76.4 million in 2022, then gained by 14.25% to $87.3 million in 2023, then jumped by 43.58% to $125.4 million in 2024, then advanced by 22.25% to $153.3 million in 2025, then slipped by 7.68% to $141.5 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $141.5 million in Q1 2026, $153.3 million in Q4 2025, and $141.8 million in Q3 2025.